Navigation Links
Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
Date:4/30/2008

first quarter of 2007.

Adjusted net income excluding selected items, was EURO 1,883 million, 1.4% lower than the 2007 first-quarter figure (EURO 1,909 million), while adjusted EPS excluding selected items was EURO 1.43, 1.4% up on the 2007 first-quarter figure (EURO 1.41).

Expressed in U.S. dollars(1), adjusted net income excluding selected items was $2,825 million, 12.9% up on the 2007 first-quarter figure, and adjusted EPS excluding selected items was $2.14, 15.7% up on the 2007 first-quarter figure.

Net debt stood at EURO 4 billion at the end of the first quarter of 2008, compared with EURO 4.2 billion at the end of 2007, after the repurchase of 17.95 million sanofi-aventis shares for a total of EURO 0.9 billion. As of April 15, 2008, the total number of shares acquired under the share repurchase program stood at 51.4 million. The Board of Directors, at its meeting of April 29, 2008, decided to cancel all these shares.

2008 Guidance(5)

Barring major adverse events, sanofi-aventis expects 2008 full-year adjusted EPS excluding selected items to grow around 7%, calculated at constant 2007 EURO/dollar parity (1.371). Sensitivity to the EURO/dollar exchange rate is estimated at 0.5% of growth for a 1-cent movement in the exchange rate.

Research and Development

Eplivanserin : Sanofi-aventis announced today that the GEMS Phase III study shows that the 5-HT2A antagonist eplivanserin in development for the treatment of insomnia characterized by sleep maintenance difficulties/night- time awakenings significantly reduces WASO (Wake time After Sleep Onset) and the number of night-time awakenings reported by the patient at 6 and 12 weeks of treatment, versus placebo. An improvement of the quality of sleep was also observed in the study.

These results confirm those of the EPLILONG study (phase III study conducted in similar conditions), which also showed that eplivanserin significantly reduces WASO and the number of night
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Tubbs Jones Introduces Resolution Encouraging STD Prevention
2. New electronic health records demonstration project encouraging step says ACP
3. Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates
4. Digirad Corporation Reports Financial Results for First-Quarter 2008
5. Essilors 2008 First-Quarter Report
6. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
7. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
8. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
9. VNUS Medical Technologies to Report First-Quarter 2008 Results and Webcast Teleconference on April 21
10. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
11. Abbott Hosts Conference Call for First-Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...Late recurrence is a risk for some pediatric cance...central nervous system, according to a new study p...National Cancer Institute . , This study was und...recurrence (after 5 years and up to 20 years) for ...sker, M.D., of the Aflac Cancer Center and Blood D...
(Date:12/4/2009)...Case Western Reserve University researchers, from ...discovered two new metabolic pathways by which pro...e, known as 4-hydroxyacids, are metabolized. The p...lomics and mass isotopomer analysis. The findings ...rug of abuse gamma-hydroxybutyrate, also known as ...
(Date:12/4/2009)... Dental tourism is a phenom...for an alternative to the high price of dental wor... search for lower priced dental care, people have ...ce as a dental tourist destination. , ...ng in business for more than 6 years, Mexican Dent...
(Date:12/4/2009)...ve a response to pressure from federal regulators ... , FRIDAY, Dec. 4 (HealthDay News) -- The ma...riday presented federal regulators with plans to c...rmaceutical companies have been under pressure fro...ind a way to stop the hundreds of fatal overdoses ...
(Date:12/4/2009)...search and surveillance urged for at-risk patient ...s) -- Some childhood cancers, particularly Ewing s...he risk of late recurrence, U.S. researchers have ...2,795 five-year survivors of the most common pedia...ncer Survivor Study. , The researchers found th...
Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2
...e of Fayette,County,s largest employers will expan...of an $8.4 million, 20-year investment by the comm...,000 grant each year through the,Fayette County Re...uction of a new,inpatient tower that will hold 56 ...
...ants for Families and Honors for Corporate Suppor...ies Affected, GURNEE, Ill., Nov. 5 This year you...oney for pediatric cancer research and,families of...uper hero costumes at this year,s Super Jake Found...
...Heart,Association and its Pharmaceutical Roundtabl...he Outcomes Research Centers initiative. The proje...troke research focusing on,the end results, or out...eart Association national board member David Spina...
...agni, President,and CEO of America,s Health Insura...ment congratulating President-elect Barack Obama:,...r his historic victory,last night. Now is the time... care challenges facing the nation. We,support cov...
...he American,Nurses Association (ANA) congratulates...tory, and looks forward to working with the new ad...change for nurses and the patients we,serve., Pre...wn a commitment to advancing the nursing professio...
...ward to health system reform in 2009, WASHINGTON,...lsen, M.D., AMA President:, "The American Medical...Obama on his successful bid for the presidency of ... President-elect Obama,s focus on expanding health...
Other Medicine News:Health News:State to Invest $8.4 Million in Uniontown Hospital's Expansion 2Health News:Super Jake Foundation Hosts 4th Annual 'Heroes Bash' on Nov. 8 to Benefit Pediatric Cancer Research 2Health News:Super Jake Foundation Hosts 4th Annual 'Heroes Bash' on Nov. 8 to Benefit Pediatric Cancer Research 3Health News:Four Medical Centers Awarded Funds to Improve Outcomes Research for Heart Disease and Stroke 2Health News:AMA Congratulates President-Elect Obama 2
(Date:12/4/2009)... , MORRISTOWN, N.J., Dec. 4 /PRNewswire-Fir...PI ), a leading global specialty pharmaceutical co... Laboratories, Inc.-Florida, filed an Abbreviated ... Drug Administration seeking approval to market it... a patent owned by Takeda Pharmaceutical Company L...
(Date:12/4/2009)... , BETHESDA, Md., Dec. 4 Drs....s for prostate-specific antigen (PSA) recurrence f...s of biochemical recurrence rate in a Phase III pi...or injection) or monthly leuprolide in prostate ca... Prostate cancer patients who received FIRMAGON 24...
(Date:12/4/2009)... , WILMINGTON, Del., Dec. 4 /PRNewswire-Firs...ed that the US Food and Drug Administration (FDA) ...ine fumarate) Extended Release Tablets as adjuncti... with Major Depressive Disorder (MDD). SEROQUEL XR...he FDA to treat both major depressive disorder as ...
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Novel K anonymity algorithm safeguards access to data 61811 1Flax and yellow flowers can produce bioethanol 10835 1Flax and yellow flowers can produce bioethanol 10835 2Parents 3A Holiday Safety Tips from Massachusetts Child Injury Lawyer Thomas M Kiley 61808 1Parents 3A Holiday Safety Tips from Massachusetts Child Injury Lawyer Thomas M Kiley 61808 2Parents 3A Holiday Safety Tips from Massachusetts Child Injury Lawyer Thomas M Kiley 61808 3
...06, Demonstrated No Reproductive Toxicity in ... Selected as Clinical Candidate, Demonstrated a 40...ce Daily Oral Dosing -, SAN DIEGO, May 22 Ardea ... preclinical data on its lead non-nucleoside,rever...806, demonstrating,no reproductive toxicity. In ad...
...ull Data Set from the TRIUMPH-1 Trial of Inhaled ...SPRING, Md., May 21 United,Therapeutics Corporati...y,Lung Rx, Inc. today announced that data from sev...nary arterial hypertension (PAH) with treprostinil...TS) meeting in Toronto,Ontario. The ATS presentati...
Other Medicine Technology:Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 2Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 3Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 4Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 3Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 4Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 5Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 6
...loped over Guidants 20-year history, the VOYAGER R...for successful treatment outcomes. It combines a n...ofile shaft,more flexible markers, and short taper...tortuous anatomy with even greater confidence, ope...
...loped over Guidants 20-year history, the VOYAGER R...for successful treatment outcomes. It combines a n...ofile shaft,more flexible markers, and short taper...tortuous anatomy with even greater confidence, ope...
...loped over Guidants 20-year history, the VOYAGER R...for successful treatment outcomes. It combines a n...ofile shaft,more flexible markers, and short taper...tortuous anatomy with even greater confidence, ope...
AFP EIA Kit
Medicine Products: